nevirapine has been researched along with Dyslipidemias in 9 studies
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.
Dyslipidemias: Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of this cross-sectional observational ('real-world') study was to investigate the effect of three HAART regimens plus stable nevirapine therapy on morphological and metabolic components of lipodystrophy in HIV-infected patients." | 7.77 | Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: a cross-sectional, observational study. ( Adorni, F; Bagni, P; Carli, F; Garlassi, E; Guaraldi, G; Luzi, K; Menozzi, M; Orlando, G; Stentarelli, C; Zona, S, 2011) |
| "The objective of this cross-sectional observational ('real-world') study was to investigate the effect of three HAART regimens plus stable nevirapine therapy on morphological and metabolic components of lipodystrophy in HIV-infected patients." | 3.77 | Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: a cross-sectional, observational study. ( Adorni, F; Bagni, P; Carli, F; Garlassi, E; Guaraldi, G; Luzi, K; Menozzi, M; Orlando, G; Stentarelli, C; Zona, S, 2011) |
| " nevirapine on the same background, in naïve HIV-1-infected patients) study compared prospectively ritonavir-boosted atazanavir (ATZ/r) 300 mg/100 mg once daily (qd) with immediate release nevirapine (NVP) 200 mg twice daily or 400 mg qd, each combined with fixed-dose tenofovir 300 mg/emtricitabine 200 mg qd in 569 ARV-naïve HIV-1-infected patients." | 2.76 | Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study). ( Andrade-Villanueva, J; Cairns, V; Clotet, B; de Rossi, L; Domingo, P; Gellermann, HJ; Podzamczer, D; Reiss, P; Rockstroh, JK; Soriano, V; Taylor, S, 2011) |
| " This is a retrospective analysis of virologic efficacy and changes in adverse neuropsychiatric effects and serum lipid levels after this switch." | 1.33 | Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profiles. ( Curtin, JM; Ward, DJ, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ji, S | 1 |
| Xu, Y | 1 |
| Han, D | 1 |
| Peng, X | 1 |
| Lu, X | 1 |
| Brockmeyer, NH | 1 |
| Wu, N | 1 |
| Pombo, M | 1 |
| Olalla, J | 1 |
| Del Arco, A | 1 |
| De La Torre, J | 1 |
| Urdiales, D | 1 |
| Aguilar, A | 1 |
| Prada, JL | 1 |
| García-Alegría, J | 1 |
| Ruiz-Mateas, F | 1 |
| Bain, AM | 1 |
| White, EA | 1 |
| Rutherford, WS | 1 |
| Rahman, AP | 1 |
| Busti, AJ | 1 |
| Roca, B | 1 |
| Podzamczer, D | 1 |
| Andrade-Villanueva, J | 1 |
| Clotet, B | 1 |
| Taylor, S | 1 |
| Rockstroh, JK | 1 |
| Reiss, P | 1 |
| Domingo, P | 1 |
| Gellermann, HJ | 1 |
| de Rossi, L | 1 |
| Cairns, V | 1 |
| Soriano, V | 1 |
| Guaraldi, G | 1 |
| Zona, S | 1 |
| Orlando, G | 1 |
| Carli, F | 1 |
| Stentarelli, C | 1 |
| Luzi, K | 1 |
| Garlassi, E | 1 |
| Menozzi, M | 1 |
| Bagni, P | 1 |
| Adorni, F | 2 |
| Rosso, R | 1 |
| Rossotti, R | 1 |
| Di Biagio, A | 1 |
| Nicolini, L | 1 |
| Orani, A | 1 |
| Viscoli, C | 1 |
| Ward, DJ | 1 |
| Curtin, JM | 1 |
| Parienti, JJ | 1 |
| Massari, V | 1 |
| Rey, D | 1 |
| Poubeau, P | 1 |
| Verdon, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efavirenz to Nevirapine Switch in HIV-1 Infected Patients With Severe Dyslipidemia: A Randomized Controlled Study[NCT00405171] | Phase 4 | 40 participants | Interventional | 2003-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for nevirapine and Dyslipidemias
| Article | Year |
|---|---|
A multimodal, evidence-based approach to achieve lipid targets in the treatment of antiretroviral-associated dyslipidemia: case report and review of the literature.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dyslip | 2008 |
Pharmacogenomics of antiretrovirals.
Topics: Alkynes; Anti-Retroviral Agents; Aryl Hydrocarbon Hydroxylases; Atazanavir Sulfate; Benzoxazines; Ce | 2008 |
2 trials available for nevirapine and Dyslipidemias
| Article | Year |
|---|---|
Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study).
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination; Dyslipidemia | 2011 |
Efavirenz to nevirapine switch in HIV-1-infected patients with dyslipidemia: a randomized, controlled study.
Topics: Alkynes; Benzoxazines; Cholesterol, LDL; Coronary Disease; Cross-Over Studies; Cyclopropanes; Dose-R | 2007 |
5 other studies available for nevirapine and Dyslipidemias
| Article | Year |
|---|---|
Changes in Lipid Indices in HIV+ Cases on HAART.
Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cholesterol, HDL; Cholesterol, LDL; Dia | 2019 |
Left ventricular hypertrophy detected by echocardiography in HIV-infected patients.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Carba | 2013 |
Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: a cross-sectional, observational study.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Composition; Body Fat Dist | 2011 |
Nevirapine-based regimens in routine clinical settings: results from a large Italian cohort of HIV-1 infected adults.
Topics: Adult; Age Factors; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Cholesterol; Cohort Studies; Databa | 2011 |
Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profiles.
Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Dyslipidemias; Female; HIV Infections; Humans; Lipids; | 2006 |